GBV-C/HIV-1 coinfection is associated with low HIV-1 viral load and high CD4+ T lymphocyte count

Miranda, Bárbara Katharine Barbosa de; Sá, Keyla Santos Guedes de; Silva, Andrea Nazaré Rangel da; Feitosa, Rosimar Neris Martins; Vallinoto, Izaura Maria Vieira Cayres; Ishak, Ricardo; Vallinoto, Antônio Carlos Rosário

doi:10.1007/s00705-017-3514-y

Cited by 12 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of HPgV among the individuals diagnosed with HIV-1 reported in this study was 26,7%, which is 9,7% higher than that reported by Miranda et al [ 41 ]. [ 38 ] The high prevalence of HPgV among HIV-1 individuals has been reported in several studies in Brazil and the world [ 42 – 44 ].…”

Section: Discussioncontrasting

confidence: 64%

Human pegivirus (HPgV, GBV-C) RNA in volunteer blood donors from a public hemotherapy service in Northern Brazil

Silva

Barata

et al. 2020

Virol J

View full text Add to dashboard Cite

Background Human pegivirus (HPgV)—formerly known as GBV-C—is a member of the Flaviviridae family and belongs to the species Pegivirus C. It is a non-pathogenic virus and is transmitted among humans mainly through the exposure to contaminated blood and is often associated with human immunodeficiency virus (HIV) infection, among other viruses. This study aimed to determine the prevalence of HPgV viremia, its association with HIV and clinical epidemiological factors, as well as the full-length sequencing and genome characterization of HPgV recovered from blood donors of the HEMOPA Foundation in Belém-PA-Brazil. Methods Plasma samples were obtained from 459 donors, tested for the presence of HPgV RNA by the RT-qPCR. From these, a total of 26 RT-qPCR positive samples were submitted to the NGS sequencing approach in order to obtain the full genome. Genome characterization and phylogenetic analysis were conducted. Results The prevalence of HPgV was 12.42%. We observed the highest prevalences among donors aged between 18 and 30 years old (16.5%), with brown skin color (13.2%) and men (15.8%). The newly diagnosed HIV-1 prevalence was 26.67%. The HPgV genotype 2 (2a and 2b) was identified. No data on viral load value was found to corroborate the protective effect of HPgV on HIV evolution. Conclusions This study provided information regarding the HPgV infection among blood donors from HEMOPA Foundation. Furthermore, we genetically characterized the HPgV circulating strains and described by the first time nearly complete genomes of genotype 2 in Brazilian Amazon.

show abstract

Section: Discussioncontrasting

confidence: 64%

Human pegivirus (HPgV, GBV-C) RNA in volunteer blood donors from a public hemotherapy service in Northern Brazil

Silva

Barata

et al. 2020

Virol J

View full text Add to dashboard Cite

show abstract

“…The prevalence of HPgV-1 infection in HTLV-1 carriers from Pará was 7.6%. This prevalence was much lower than that observed in individuals with HIV in the same region (North Region, 17.0%) [24] and in the South Region of Brazil (21.7%) [20] as well as in HIV carriers from China (23.4%) [7] and Indonesia (88.8%) [11]. We observed a prevalence of…”

Section: Discussioncontrasting

confidence: 74%

Low prevalence of human pegivirus 1 (HPgV-1) in HTLV-1 carriers from Belém, Pará, North Region of Brazil

et al. 2020

View full text Add to dashboard Cite

Data Availability Statement: All relevant data are within the manuscript. respectively. No significant differences were found when comparing any clinical or demographic data between groups. Conclusion This study indicated that the prevalence of HPgV-1 infection is low in HTLV-1 carriers in Belé m, Pará , and probably does not alter the clinical course of HTLV-1 infection, however, further studies are still needed.

show abstract

“…However, after ART initiation, this study did not observe an association between HPgV-1 and the median HIV-1 VL or CD4+ T-cell counts. Some studies have indicated that HPgV-1 may act to reduce T-cell activation [41–43], benefiting coinfected individuals even after the introduction of therapy, with a likely synergy between both viruses [15, 42]. The beneficial effects of HPgV-1 have already been associated with other viral infections, such as those with HCV [44] and Ebola [16].…”

Section: Discussionmentioning

confidence: 99%

Molecular and Clinical Profiles of Human Pegivirus Type 1 Infection in Individuals Living with HIV-1 in the Extreme South of Brazil

Mota

Finger‐Jardim

Silva

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Human pegivirus type 1 (HPgV-1) infection has been associated with a beneficial effect on the prognosis of human immunodeficiency virus type 1 (HIV-1)-coinfected individuals. However, the mechanisms involved in this protection are not yet fully elucidated. To date, circulating HPgV-1 genotypes in HIV-1-infected individuals have not yet been identified in the extreme south of Brazil. The present study aimed to determine the genotypic circulation of HPgV-1 and the influence of HPgV-1 status and persistence time on the evolution of HIV-1 infection. A retrospective cohort of 110 coinfected individuals was analyzed. Samples were subjected to viral RNA extraction, cDNA synthesis, nested PCR, and genotyping. Genotypes 1 (2.8%), 2 (47.9% of subtype 2a and 42.3% of subtype 2b), and 3 (7%) were identified. In antiretroviral treatment-naïve subjects HPgV-1 subtype 2b was associated with lower HIV-1 viral load (VL) rates (p = 0.04) and higher CD4+ T-cell counts (p = 0.03) than was subtype 2a, and the positivity for HPgV-1 was associated with higher CD4+ T-cell counts (p = 0.02). However, there was no significant difference in HIV-1 VL between HPgV-1-positive and HPgV-1-negative subjects (p = 0.08). There was no significant association between the different groups in HPgV-1 persistence and median HIV-1 VL (p = 0.66) or CD4+ T-cell counts (p = 0.15). HPgV-1 subtype 2b is associated with better prognosis of HIV-1 infection. Although HPgV-1 infection is persistent, our data suggest that the time of infection does not influence HIV-1 VL or CD4+ T-cell counts in coinfected subjects.

show abstract

GBV-C/HIV-1 coinfection is associated with low HIV-1 viral load and high CD4+ T lymphocyte count

Cited by 12 publications

References 46 publications

Human pegivirus (HPgV, GBV-C) RNA in volunteer blood donors from a public hemotherapy service in Northern Brazil

Human pegivirus (HPgV, GBV-C) RNA in volunteer blood donors from a public hemotherapy service in Northern Brazil

Low prevalence of human pegivirus 1 (HPgV-1) in HTLV-1 carriers from Belém, Pará, North Region of Brazil

Molecular and Clinical Profiles of Human Pegivirus Type 1 Infection in Individuals Living with HIV-1 in the Extreme South of Brazil

Contact Info

Product

Resources

About